Divi's Laboratories (DIVISLAB) Aktievy
Divi's Laboratories Limited är verksamt inom tillverkning och försäljning av generiska aktiva farmaceutiska ingredienser (API), mellanprodukter och nutraceuticals i Indien, Nordamerika, Asien, Europa och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Divi's Laboratories Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | ₹6,797.50 |
| 52 veckors högsta | ₹7,071.50 |
| 52 veckors lägsta | ₹5,636.50 |
| Beta | 0.22 |
| 1 månads förändring | 5.67% |
| 3 månaders förändring | 6.07% |
| 1 års förändring | 2.50% |
| 3 års förändring | 92.82% |
| 5 års förändring | 60.61% |
| Förändring sedan börsintroduktionen | 77,034.75% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Analysartikel • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Recent updates
Uppdatering av berättelse • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Analysartikel • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Uppdatering av berättelse • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.
Uppdatering av berättelse • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Uppdatering av berättelse • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Uppdatering av berättelse • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Uppdatering av berättelse • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Uppdatering av berättelse • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Uppdatering av berättelse • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Analysartikel • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...Uppdatering av berättelse • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Uppdatering av berättelse • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Analysartikel • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Uppdatering av berättelse • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Analysartikel • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...Analysartikel • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Uppdatering av berättelse • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Analysartikel • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...Uppdatering av berättelse • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.Analysartikel • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...Analysartikel • Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Key Insights Divi's Laboratories' Annual General Meeting to take place on 11th of August CEO Kiran Divi's total...Analysartikel • Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Divi's Laboratories Limited ( NSE:DIVISLAB ) shareholders are probably feeling a little disappointed, since its shares...
Ny berättelse • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Aktieägarnas avkastning
| DIVISLAB | IN Life Sciences | IN Marknad | |
|---|---|---|---|
| 7D | -0.9% | -1.5% | 2.1% |
| 1Y | 2.5% | 0.5% | 0.8% |
Avkastning vs industri: DIVISLAB översteg Indian Life Sciences branschen som gav 0.5 % under det senaste året.
Avkastning vs Marknaden: DIVISLAB översteg Indian marknaden som gav 0.8 % under det senaste året.
Prisvolatilitet
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 2.8% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.3% |
| 10% least volatile stocks in IN Market | 4.8% |
Stabil aktiekurs: DIVISLAB har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Indian.
Volatilitet över tid: DIVISLAB s veckovolatilitet ( 3% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1990 | 10,542 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited är verksamt inom tillverkning och försäljning av generiska aktiva farmaceutiska ingredienser (API), mellanprodukter och näringsläkemedel i Indien, Nordamerika, Asien, Europa och internationellt. Företaget utför även kontraktstillverkning av API:er och mellanprodukter med anpassad syntes och levererar en rad karotenoider, såsom betakaroten, astaxanthin, lykopen och kantaxanthin, samt andra färdiga former, inklusive lutein, och vitaminer till livsmedels-, kosttillskotts- och fodertillverkningsindustrin. Företaget exporterar också sina produkter.
Divi's Laboratories Limited Sammanfattning av grunderna
| DIVISLAB grundläggande statistik | |
|---|---|
| Börsvärde | ₹1.80t |
| Vinst(TTM) | ₹25.68b |
| Intäkter(TTM) | ₹105.60b |
70.3x
P/E-förhållande17.1x
P/S-förhållandeÄr DIVISLAB övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| DIVISLAB resultaträkning (TTM) | |
|---|---|
| Intäkter | ₹105.60b |
| Kostnad för intäkter | ₹40.93b |
| Bruttovinst | ₹64.67b |
| Övriga kostnader | ₹38.99b |
| Intäkter | ₹25.68b |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 96.73 |
| Bruttomarginal | 61.24% |
| Nettovinstmarginal | 24.32% |
| Skuld/egenkapitalförhållande | 0% |
Hur har DIVISLAB utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.4%
Aktuell utdelningsavkastning31%
UtbetalningskvotGer DIVISLAB en tillförlitlig utdelning?
Se DIVISLAB utdelningshistorik och jämförelsetal| Divi's Laboratories datum för utdelning | |
|---|---|
| Ex utdelningsdag | Jul 24 2026 |
| Utbetalningsdag för utdelning | Sep 09 2026 |
| Dagar till Ex-utdelning | 56 days |
| Dagar till utdelningsdag | 103 days |
Ger DIVISLAB en tillförlitlig utdelning?
Se DIVISLAB utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/28 23:51 |
| Aktiekurs vid dagens slut | 2026/05/27 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Divi's Laboratories Limited bevakas av 47 analytiker. 29 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |